CtDNA-guided therapy for stage III-IVA stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether personalized adjuvant therapy, guided by ctDNA levels in your blood, can reduce the risk of cancer returning after surgery for stage III or IVA stomach or gastroesophageal junction cancer. It is for individuals with HER2-negative disease who are candidates for surgery and have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IVA stomach or gastroesophageal junction cancer that has not spread to other organs.
- Your cancer is HER2-negative and you have not had any previous treatment for it.
- You are between 18 and 75 years old and in reasonably good health (able to do most daily activities).
- Your liver, kidneys, and blood counts are within normal ranges.
- You have not had other cancers in the last 5 years (except for some skin or early stage cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.